An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 243 participants.

Also called NCT02633293

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 243 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02633293
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02633293. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-15 (actual); primary completion 2021-08-01 (actual). Results posted on 2022-12-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Condition
Interstitial Lung Disease
Condition
Combined Pulmonary Fibrosis and Emphysema
Intervention (Drug)
Inhaled Treprostinil
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02633293
Content hash
aa4ec330ea636131ba579e02e8242be42bd58fe0ebd73ddf81a7d249e30bc7d0